Topiramate vs Erenumab
from HeadWise
The HER-MES trial is a newly published study comparing the tolerability and efficacy of topiramate (Topamax) and erenumab (Aimovig). The results of this trial could impact prescribing practices and payor policies. Tune in this afternoon for this episode of Heads UP as Lindsay Weitzel, PhD, and Tim Smith, MD, discuss the important aspects of the HER-MES trial.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of HeadWise?
This episode is 19 minutes long.
When was this HeadWise episode published?
This episode was published on January 14, 2022.
Can I download this HeadWise episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.